BIOA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

BI

Mkt Cap

$221.5M

Volume

714.96K

Next Earnings

November 5th

Loading chart

BI

BIOABioAge Labs, Inc. Common Stock

BIOA

Pay with—

Available Balance0.00

BI

Mkt Cap

$222.1M

Volume

714.96K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

BioAge Labs to Present at Upcoming Investor ConferencesBioAge Labs announced the first participant has been dosed in QUELL-CV, a Phase 2 proof-of-concept trial evaluating BGE-102, an oral NLRP3 inhibitor, in patients with elevated cardiovascular risk and systemic inflammation. Topline data is anticipated in the second half of 2026. The company also announced participation in three upcoming investor conferences in September 2026.GlobeNewswire Inc. · Sep 2, 2026

BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business UpdatesBioAge Labs announced the first participant dosing in QUELL-CV, a Phase 2 trial of BGE-102, an oral NLRP3 inhibitor for patients with obesity and elevated inflammation. Phase 1 data showed BGE-102 achieved up to 98% suppression of IL-1β and 86% median hsCRP reductions. The company also plans to initiate QUELL-DME trial in diabetic macular edema in mid-2026. BioAge reported Q2 2026 net loss of $26.1 million with $381.3 million in cash, sufficient to fund operations through 2029.GlobeNewswire Inc. · Aug 5, 2026

BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular RiskBioAge Labs announced the first participant has been dosed in QUELL-CV, a Phase 2 proof-of-concept trial evaluating BGE-102, an oral NLRP3 inhibitor for cardiovascular risk reduction. The randomized, double-blind, placebo-controlled trial will enroll approximately 160 participants with obesity and elevated inflammation across three dose levels. Phase 1 results showed BGE-102 achieved median hsCRP reductions of 86% and was well tolerated. Topline data are anticipated in the second half of 2026, with an additional Phase 1b/2a trial in diabetic macular edema planned for mid-2026.GlobeNewswire Inc. · Jun 16, 2026

BioAge Labs to Present at Upcoming Investor ConferencesBioAge Labs, a clinical-stage biotechnology company, announced it will participate in the Jefferies Global Healthcare Conference (June 3-4, 2026) and Goldman Sachs Global Healthcare Conference (June 8-10, 2026). Company executives will present and hold one-on-one meetings at both events. BioAge is developing BGE-102, an NLRP3 inhibitor for cardiometabolic diseases, with Phase 2 cardiovascular data expected by end of 2026.GlobeNewswire Inc. · May 22, 2026

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative MarketsCell-based therapies are emerging as a transformative approach in healthcare, with the global cell therapy market expected to grow from $4.7 billion in 2023 to over $20 billion by 2030. Several biotech companies announced significant milestones: Avaí Bio and Austrianova completed a Master Cell Bank for α-Klotho anti-aging therapy; Geron presented real-world evidence for RYTELO in myelodysplastic syndromes; BioAge Labs reported Phase 1 results for BGE-102 showing strong inflammatory biomarker reductions; Lineage Cell Therapeutics presented 3-year data for OpRegen cell therapy in geographic atrophy; and Fate Therapeutics advanced FT819 CAR T-cell therapy with FDA recognition.Benzinga · May 20, 2026

BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRPBioAge Labs announced positive Phase 1 results for BGE-102, an oral NLRP3 inhibitor, showing potential best-in-class reductions in hsCRP (high-sensitivity C-reactive protein) of ≥85% at both 60 mg and 120 mg once-daily doses in participants with obesity and elevated inflammation. The drug was well tolerated across all dose levels. The company plans to initiate a Phase 2 cardiovascular risk proof-of-concept trial in mid-2026 with results expected by year-end, and a Phase 1b/2a trial in diabetic macular edema also planned for mid-2026.GlobeNewswire Inc. · Apr 21, 2026

BioAge Announces Pricing of Upsized $115.0 Million Public OfferingBioAge Labs (Nasdaq: BIOA), a clinical-stage biopharmaceutical company, announced the pricing of an upsized underwritten public offering of 5.9 million shares at $19.50 per share, raising approximately $115 million in gross proceeds. The company plans to use the funds for research, development, and manufacturing of its product candidates, including the lead candidate BGE-102 (an NLRP3 inhibitor), APJ agonist programs, and general corporate purposes. The offering is expected to close on January 23, 2026.GlobeNewswire Inc. · Jan 22, 2026

BioAge Announces Proposed Public OfferingBioAge Labs (NASDAQ: BIOA), a clinical-stage biopharmaceutical company focused on metabolic diseases and aging biology, announced a proposed underwritten public offering of up to $75 million in common stock, with an additional $11.25 million option for underwriters. The company plans to use proceeds for research, development, and manufacturing of product candidates including BGE-102, NLRP3, and APJ programs. Goldman Sachs, Piper Sandler, and Citigroup are acting as joint book-running managers.Benzinga · Jan 20, 2026

BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026BioAge Labs announced expansion of its BGE-102 NLRP3 inhibitor development program into ophthalmology, planning to initiate a Phase 1b/2a proof-of-concept trial in diabetic macular edema (DME) patients in mid-2026. The oral therapy has demonstrated favorable tolerability and robust reductions in inflammatory biomarkers in ongoing Phase 1 trials, with potential to reduce treatment burden compared to current intravitreal injection therapies. Results from the DME trial are anticipated in mid-2027, running parallel to a cardiovascular risk Phase 2a trial with results expected in 2H26.GlobeNewswire Inc. · Jan 20, 2026

2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot PoleThe article discusses why BioAge Labs is a risky investment, highlighting its early-stage clinical candidate BGE-102 in weight management and the competitive landscape of obesity treatments.The Motley Fool · Dec 13, 2025

to start trading

BI

BIOABioAge Labs, Inc. Common Stock

BIOA

Pay with—

Available Balance0.00

Your PositionYou don't own any BIOA yet.

Related Tickers

Earnings